M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome
German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that it has initiated a Phase IIa clinical trial of BAY 3401016, an investigational monoclonal antibody designed to block Semaphorin 3A (Sema3A), a protein implicated in kidney damage in Alport...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search